AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
MARCH 23, 2023
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda aliu Thu, 03/23/2023 - 10:23
Fierce Pharma
MARCH 23, 2023
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda aliu Thu, 03/23/2023 - 10:23
Fierce Pharma
OCTOBER 20, 2023
Moving drugs into early-stage cancers is in vogue these days. Moving drugs into early-stage cancers is in vogue these days. Roche has just posted a trial win for its targeted lung cancer therapy Alecensa that should enable earlier use, while eliciting a sense of déjà vu from a study of AstraZeneca’s Tagrisso.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 13, 2022
The post Nordic Nanovector board resigns en masse as merger bid fails appeared first on. It is also running low on cash reserves, which were NOK 287 million (around $29 million) at the midpoint of the year and have been predicted to fall below NOK 100 million by the end of the year. Image by Alexander Fox | PlaNet Fox from Pixabay .
pharmaphorum
JANUARY 30, 2024
Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year
European Pharmaceutical Review
OCTOBER 17, 2022
S) in the enteric nervous system (ENS) and central nervous system (CNS). S in the ENS and CNS, displacing and preventing aggregation, improving neural signalling of enteric neurons between the digestive system and brain via the vagus nerve. PD dementia (PDD) is largely caused by aggregation of the protein alpha-synuclein (?S)
Pharmaceutical Technology
MAY 30, 2023
Canada’s health technology assessment bodies, including the Canadian agency for drugs and technologies in health (CADTH) and the institut national d’excellence en santé et en services sociaux (INESSS) have both reviewed Vabysmo and recommended it to treat nAMD and DME.
Impetus Digital
JULY 26, 2022
The client’s main objectives were to: En gag e headache specialists on a monthly basis to review marketing and patient education resources and drafts asynchronously. Leverage a variety of cutting-edge virtual tools to gather targeted and collaborative feedback and insights, while avoiding digital collaboration fatigue.
Let's personalize your content